Admescope

ISSX Europe 2026 is just around the corner, and I'm looking forward to spending a few days in Basel with colleagues, clients and fellow scientists from across the DMPK and ADME-Tox community. One of the things I enjoy most about ISSX is the opportunity to discuss the challenges that sit behind the data. Whether it's understanding unexpected metabolism, designing the right DDI strategy, improving candidate selection or navigating complex ADME properties, the most valuable conversations often happen outside of the presentation halls. If you're attending ISSX Europe this year and would like to discuss an ongoing programme or explore approaches to ADME-Tox and DMPK strategy, I'd be delighted to connect. I'll be attending alongside my colleague Laszlo Szilagyi Looking forward to seeing many familiar faces in Basel and meeting new ones as well! Arrange a meeting 👉https://lnkd.in/d7Uc6WJw #ISSX2026 #ADMETox #DMPK #DrugDiscovery #DrugDevelopment

I’m excited to be attending ISSX Europe 2026 in Basel from 29 June to 2 July and look forward to engaging with researchers, scientists, and industry partners from across the drug discovery and development community. Every programme faces critical decisions along the journey from discovery to development. Having the right ADME-Tox, DMPK and bioanalytical strategy in place can make a significant difference in identifying risks early and moving forward with confidence. ISSX provides a fantastic opportunity to exchange ideas, discuss emerging challenges and learn from the latest scientific advances shaping our industry. If you'll be attending and would like to discuss an upcoming project, current challenges or simply connect, please feel free to reach out and arrange a meeting. Looking forward to seeing you in Basel. Book a meeting 👉 https://lnkd.in/evb4yu2Q #ISSX2026 #ADMETox #DMPK #DrugDiscovery #Pharma

Heading to ISSX Europe 2026 in Basel? The Admescope team will be attending throughout the event, and we'd love to connect with fellow scientists and drug discovery teams. Whether you're looking for support with: 🔹 In vitro metabolism and biotransformations 🔹 Drug-drug interaction studies 🔹 Quantitative bioanalysis 🔹 In vivo DMPK 🔹 Safety metabolism 🔹 In vitro toxicology 🔹 Integrated ADME-Tox strategies Our team will be available to discuss your programme and explore how we can help generate the data needed to make confident development decisions. Attending from Admescope: - Miia Kovalainen, Head of Business Development - Laszlo Szilagyi, Director of Business Development - Iiro Kiiski, Senior Research Scientist Book a meeting today.

DILI is one of the leading causes of late-stage drug failure. Join our live webinar to explore how in vitro strategies can help identify hepatotoxicity risks earlier in development. In this session, our expert Dr. Sanna-Mari Aatsinki will cover: 🔹 Key biological mechanisms behind DILI 🔹 Why traditional preclinical models can fall short 🔹 How in vitro approaches support earlier decision-making 🔹 Emerging strategies shaping DILI assessment 📅 May 6th 🕐 9 AM EDT | 2 PM BST | 3 PM CEST Register now to secure your place 👇

Many drug candidates fail due to DILI at late stages of development. Join our live webinar with Dr. Sanna-Mari Aatsinki, Head of Drug-Drug Interactions and In Vitro Toxicology at Admescope, a Symeres company, to learn how in vitro strategies can help identify hepatotoxicity risks earlier. 📅 May 6th 2026 🕐 9 AM EDT | 2 PM BST | 3 PM CEST 👉 Reserve your spot today

Drug-induced toxicity—especially hepatotoxicity (DILI)—remains a leading cause of late-stage drug development failure. Our new in vitro toxicology e-book highlights key toxicity risks and screening strategies used in early drug discovery. Learn more about: 🔬 Hepatotoxicity, cardiotoxicity, genotoxicity, nephrotoxicity & neurotoxicity 🧪 Liver-specific toxicities: steatosis, phospholipidosis & cholestasis 🚀 NAMs, including 3D models, organ-on-chip & in silico approaches 👉 See the link in the comments to download the e-book! #InVitroToxicology #Hepatotoxicity #DILI #DrugDiscovery #NAMs #ADME #Toxicology